| Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive … PM Miettunen, A Narendran, A Jayanthan, EM Behrens, RQ Cron Rheumatology 50 (2), 417-419, 2011 | 299 | 2011 |
| Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice C Lee, A Fotovati, J Triscott, J Chen, C Venugopal, A Singhal, C Dunham, ... Stem cells 30 (6), 1064-1075, 2012 | 89 | 2012 |
| Curcumin Blocks Kv11.1 (erg) Potassium Current and Slows Proliferation in the Infant Acute Monocytic Leukemia Cell line THP-1 U Banderali, D Belke, A Singh, A Jayanthan, WR Giles, A Narendran Cellular Physiology and Biochemistry 28 (6), 1169-1180, 2011 | 42 | 2011 |
| Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting … A Singh, X Lun, A Jayanthan, H Obaid, Y Ruan, D Strother, SN Chi, ... Molecular Oncology 7 (3), 497-512, 2013 | 40 | 2013 |
| Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity LM Hawkins, AA Jayanthan, A Narendran Pediatric research 57 (3), 430-437, 2005 | 39 | 2005 |
| Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition A Singh, A Jayanthan, A Farran, AN Elwi, SW Kim, P Farran, A Narendran Leukemia research 35 (12), 1649-1657, 2011 | 38 | 2011 |
| Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors X Lun, Y Ruan, A Jayanthan, DJ Liu, A Singh, T Trippett, J Bell, P Forsyth, ... Molecular oncology 7 (5), 944-954, 2013 | 37 | 2013 |
| Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition A Jayanthan, D Bernoux, P Bose, K Riabowol, A Narendran Cancer Cell International 11, 1-11, 2011 | 30 | 2011 |
| Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic … A Jayanthan, SC Howard, T Trippett, T Horton, JA Whitlock, L Daisley, ... Leukemia & lymphoma 50 (7), 1174-1182, 2009 | 29 | 2009 |
| Cytotoxicity, drug combinability, and biological correlates of ABT‐737 against acute lymphoblastic leukemia cells with MLL rearrangement A Jayanthan, A Incoronato, A Singh, C Blackmore, D Bernoux, V Lewis, ... Pediatric blood & cancer 56 (3), 353-360, 2011 | 24 | 2011 |
| Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics A Narendran, L Coppes, A Jayanthan, M Coppes, B Teja, D Bernoux, ... Journal of neuro-oncology 90, 171-180, 2008 | 21 | 2008 |
| The dawn of targeted therapies for triple negative breast cancer (TNBC): A snapshot of investigational drugs in phase I and II trials M Huynh, MR Pambid, A Jayanthan, A Dorr, G Los, SE Dunn Expert opinion on investigational drugs 29 (11), 1199-1208, 2020 | 20 | 2020 |
| Childhood acute lymphoblastic leukemia (ALL) presenting with severe osteolysis: a model to study leukemia-bone interactions and potential targeted therapeutics A Jayanthan, PMH Miettunen, A Incoronato, CL Ortiz-Neira, VA Lewis, ... Pediatric hematology and oncology 27 (3), 212-227, 2010 | 17 | 2010 |
| RSK2: A promising therapeutic target for the treatment of triple-negative breast cancer M Huynh, A Jayanthan, MR Pambid, G Los, SE Dunn Expert opinion on therapeutic targets 24 (1), 1-5, 2020 | 16 | 2020 |
| Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy Y Ruan, A Kovalchuk, A Jayanthan, X Lun, Y Nagashima, O Kovalchuk, ... Neuro-oncology 17 (6), 822-831, 2015 | 16 | 2015 |
| Aurora kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents A Jayanthan, Y Ruan, TH Truong, A Narendran PLoS One 9 (7), e102741, 2014 | 16 | 2014 |
| Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells A Jayanthan, TM Cooper, KA Hoeksema, S Lotfi, E Woldum, VA Lewis, ... Leukemia & Lymphoma 54 (7), 1505-1516, 2013 | 12 | 2013 |
| Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL … KA Hoeksema, A Jayanthan, T Cooper, L Gore, T Trippett, J Boklan, ... OncoTargets and therapy, 149-168, 2011 | 10 | 2011 |
| Targeting the proteasome in refractory pediatric leukemia cells: characterization of effective cytotoxicity of carfilzomib L Swift, A Jayanthan, Y Ruan, R Anderson, J Boklan, T Trippett, ... Targeted Oncology 13, 779-793, 2018 | 7 | 2018 |
| First-in-human phase 1/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer. M Beeram, P Chalasani, JS Wang, LA Mina, RA Shatsky, MS Trivedi, ... Journal of Clinical Oncology 39 (15_suppl), e13043-e13043, 2021 | 6 | 2021 |
